Evidence map›Paper›PMID 34569060›Full record

ArticleInternational journal of cancer2022

Molecular profiles and urinary biomarkers of upper tract urothelial carcinomas associated with aristolochic acid exposure.

Sandra Karanović, Maude Ardin, Zuojian Tang, Karla Tomić, Stephanie Villar, Claire Renard, Elisa Venturini, Adam H Lorch, Daniel S Lee, Želimir Stipančić and 10 more

Open access · hybridAbstract read
In one paragraph

Article in International journal of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 8 institutions in 4 countries.

Sandra KaranovićDepartment of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.
Maude ArdinEpigenomics and Mechanisms Branch, International Agency for Research on Cancer, WHO, Lyon, France.
Zuojian TangInstitute for Systems Genetics, New York University Langone Medical Center, New York, New York, USA.
Karla TomićDepartment of Pathology, General Hospital Dr. Josip Benčević, Slavonski Brod, Croatia.
Stephanie VillarEpigenomics and Mechanisms Branch, International Agency for Research on Cancer, WHO, Lyon, France.
Claire RenardEpigenomics and Mechanisms Branch, International Agency for Research on Cancer, WHO, Lyon, France.
Elisa VenturiniOffice for Collaborative Science, New York University Langone Medical Center, New York, New York, USA.
Adam H LorchBiochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Daniel S LeeOffice for Collaborative Science, New York University Langone Medical Center, New York, New York, USA.
Želimir StipančićDepartment for Dialysis Odžak, County Hospital Orašje, Odžak, Bosnia and Herzegovina.
Neda SladeDivision of Molecular Medicine, Institute Ruđer Bošković, Zagreb, Croatia.
Ivana Vuković BrinarDepartment of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.
Damir DittrichDepartment of Urology, General Hospital Dr. Josip Benčević, Slavonski Brod, Croatia.
Krešimir KarlovićDepartment of Urology, General Hospital Dr. Josip Benčević, Slavonski Brod, Croatia.
Fran BorovečkiDepartment for Functional Genomics, Center for Translational and Clinical Research, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.
Kathleen G DickmanDepartment of Medicine, Stony Brook University, Stony Brook, New York, USA.
Magali OlivierEpigenomics and Mechanisms Branch, International Agency for Research on Cancer, WHO, Lyon, France.
Arthur P GrollmanDepartment of Medicine, Stony Brook University, Stony Brook, New York, USA.
Bojan JelakovićDepartment of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.
Jiri ZavadilEpigenomics and Mechanisms Branch, International Agency for Research on Cancer, WHO, Lyon, France.ORCID 0000-0003-0640-5562
Centre international de recherche sur le cancer · FRUniversity Hospital Centre Zagreb · HRNYU Langone Health · USUniversity of Slavonski Brod · HRStony Brook University · USNorthwestern University · USPublic Health Institute of the Republic of Srpska · BARuđer Bošković Institute · HR

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 1985 to 2026
$83.1M
SYNTHETIC & ANALYTICALP01ES004068 · NIEHS · STATE UNIVERSITY NEW YORK STONY BROOK · PI IDEN, CHARLES R · 1987 to 2011
$14.1M
Etiology of Balkan endemic nephropathyR03TW007042 · FIC · STATE UNIVERSITY NEW YORK STONY BROOK · PI GROLLMAN, ARTHUR PATRICK · 2006 to 2008
$111k
FIC NIH HHS R03 TW007042NCI NIH HHS P30 CA016087NIEHS NIH HHS P01 ES004068World Health Organization 001
6 · The paper itself

Abstract

Recurrent upper tract urothelial carcinomas (UTUCs) arise in the context of nephropathy linked to exposure to the herbal carcinogen aristolochic acid (AA). Here we delineated the molecular programs underlying UTUC tumorigenesis in patients from endemic aristolochic acid nephropathy (AAN) regions in Southern Europe. We applied an integrative multiomics analysis of UTUCs, corresponding unaffected tissues and of patient urines. Quantitative microRNA (miRNA) and messenger ribonucleic acid (mRNA) expression profiling, immunohistochemical analysis by tissue microarrays and exome and transcriptome sequencing were performed in UTUC and nontumor tissues. Urinary miRNAs of cases undergoing surgery were profiled before and after tumor resection. Ribonucleic acid (RNA) and protein levels were analyzed using appropriate statistical tests and trend assessment. Dedicated bioinformatic tools were used for analysis of pathways, mutational signatures and result visualization. The results delineate UTUC-specific miRNA:mRNA networks comprising 89 miRNAs associated with 1,862 target mRNAs, involving deregulation of cell cycle, deoxyribonucleic acid (DNA) damage response, DNA repair, bladder cancer, oncogenes, tumor suppressors, chromatin structure regulators and developmental signaling pathways. Key UTUC-specific transcripts were confirmed at the protein level. Exome and transcriptome sequencing of UTUCs revealed AA-specific mutational signature SBS22, with 68% to 76% AA-specific, deleterious mutations propagated at the transcript level, a possible basis for neoantigen formation and immunotherapy targeting. We next identified a signature of UTUC-specific miRNAs consistently more abundant in the patients' urine prior to tumor resection, thereby defining biomarkers of tumor presence. The complex gene regulation programs of AAN-associated UTUC tumors involve regulatory miRNAs prospectively applicable to noninvasive urine-based screening of AAN patients for cancer presence and recurrence.

Indexed as

MutationAristolochic AcidsBiomarkers, TumorCarcinoma, Transitional CellExomeFollow-Up StudiesGene Expression Regulation, NeoplasticHumansMicroRNAsPrognosisProteomeRNA, MessengerUrinary Bladder Neoplasmsaristolochic acid IAristolochic AcidsBiomarkers, TumorMicroRNAsProteomeRNA, Messengeraristolochic acidmassively parallel sequencingtranscriptome profilingupper tract urothelial carcinomaurine miRNA

Identifiers

PMID34569060
PMCPMC8627473
OpenAlexW3202238776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.